BioNxt Solutions Inc (OTCMKTS:BNXTF) Stock In Focus After Latest News
On May 8, BioNxt Solutions Inc (OTCMKTS:BNXTF) was in focus after it announced that it had been successful in completing a human pilot study for a leading generic drug company, based out of Europe. BioNxt Solutions announced that it had managed to develop an oral dissolvable narcotics product.
Trading Data
On Monday, BNXTF stock ended flat at $0.4896 with more than 100 shares, compared to its average volume of 1.58K shares. The stock moved within a range of $0.4896 – 0.4896 after opening trading at $0.4896.
BioNxt Successfully Completes Pilot Study for Contract Development Customer
Additionally, the company also noted that it had also managed to complete the comparative bioavailability study. The Chief Executive Officer of BioNxt Solutions Hugh Rogers spoke about the company’s aims and objectives too. He noted that the company was actively working on the development of a pipeline of contract and in-house drug formulation initiatives.
He went on to add that everyone at the company was pleased at the recent successes of its contract development initiatives. That provided a significant opportunity to the company to expand its capabilities to commercial manufacturing from drug development. That would be possible once the contract products and in-house formulations move towards commercialization.
Vektor Pharma TF GmbH is the company’s fully owned subsidiary and functions as a German medicine development and manufacturing entity. It also owns narcotics licenses. It has been the leader in testing, designing and manufacturing of similar products for over a decade.
